Neglected Diseases and Drug Discovery
192,99 €
inkl. MwSt.
Versandkostenfrei*
Versandfertig in über 4 Wochen
  • Gebundenes Buch

There are ~8 million deaths every year from neglected tropical diseases (NTDs) in the underdeveloped world, whilst drug discovery focus and practice is only recently taking on greater urgency and embracing the latest technologies. The aim of this book is to present a state-of-the-art review of drug discovery in respect of NTDs and to highlight best practice to guide ongoing drug discovery effort, to raise awareness and promote debate in neglected disease areas that still have unmet medical need. Neglected Diseases and Drug Discovery, details nearly all of the key diseases that fall into this…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
There are ~8 million deaths every year from neglected tropical diseases (NTDs) in the underdeveloped world, whilst drug discovery focus and practice is only recently taking on greater urgency and embracing the latest technologies. The aim of this book is to present a state-of-the-art review of drug discovery in respect of NTDs and to highlight best practice to guide ongoing drug discovery effort, to raise awareness and promote debate in neglected disease areas that still have unmet medical need. Neglected Diseases and Drug Discovery, details nearly all of the key diseases that fall into this class. It sets out to make a critical appraisal of ongoing research with a focus on the key science that has led to breakthroughs, especially from a medicinal chemistry perspective. The book covers in great depth current efforts in the malaria, trypanosomatid, flavivirus and tuberculosis fields, wherein an upsurge in research efforts has been evident in recent times. Additionally, there is some focus on the 'neglected' neglected diseases, notably diarrhea, helminths, HIV (in worldwide terms) and lower respiratory tract infections. In respect of the more publicised disease areas such as malaria there is a review of each disease and established compounds, mechanistic classes and new horizons. In the more under-publicised areas the chapters seek to highlight the pressing need for better and more widely available treatments Written by a team of experienced experts the book will prove to be an invaluable guide to successful practice in NTDs highlighting ongoing and new drug discovery efforts in this field. It will aid both researchers and the general reader, by summarising the key learning to date and provide a clear overview of the challenges that remain.
Autorenporträt
Michael J Palmer is a Senior Principal Scientist at Pfizer. He has worldwide medicinal chemistry and drug discovery based experience across many different therapeutic areas. He is a member of the drug discovery teams responsible for carduraTM, additional cardiovascular agents that progressed to man, and cardiovascular and antiviral agents in Phase I and II stages of development. Timothy NC Wells is Chief Scientific Officer at Medicines for Malaria Venture, Geneva, Switzerland.